This article summarized the latest R&D progress of Ceftazidime, the Mechanism of Action for Ceftazidime, and the drug target R&D trends for Ceftazidime.

KRAS G12D differs from KRAS G12C only in the type of amino acid mutation on the same codon.

This article summarized the latest R&D progress of Cefadroxil, the Mechanism of Action for Cefadroxil, and the drug target R&D trends for Cefadroxil.

Daiichi Sankyo has declared that the first patient has been dosed in a first-in-human Phase 1/2 examination evaluating DS-3939.

The Cannabinoid receptor 1 (CB1), as one of the most classic receptors of the Endocannabinoid system (ECS), is a G protein-coupled membrane receptor.

This article summarized the latest R&D progress of Cefaclor, the Mechanism of Action for Cefaclor, and the drug target R&D trends for Cefaclor.

VBI Vaccines Inc., a biopharma company specializing in immunology, announced that its cancer immunotherapy vaccine candidate, VBI-1901, has begun a Phase 2b trial in patients with first recurrence glioblastoma.

This article summarized the latest R&D progress of Adenine, the Mechanism of Action for Adenine, and the drug target R&D trends for Adenine.

CCR5, or C-C chemokine receptor type 5, is a protein receptor found on the surface of certain immune cells, including T cells and macrophages.

This article summarized the latest R&D progress of Acepromazine, the Mechanism of Action for Acepromazine, and the drug target R&D trends for Acepromazine.

4D Molecular Therapeutics has begun the Dose Confirmation stage of their Phase 2 SPECTRA trial, enrolling their first patient. The trial evaluates intravitreal 4D-150 for treating diabetic macular edema.

This article summarized the latest R&D progress of Metolazone, the Mechanism of Action for Metolazone, and the drug target R&D trends for Metolazone.